Begin main content

Optimal Use of Minimally Invasive Glaucoma Surgery: A Health Technology Assessment

Published on: March 14, 2019
Project Number: OP0532-000
Product Line: Optimal Use
Result type: Report
Expected Completion Date: March 22, 2019

Glaucoma is a leading cause of blindness. A range of surgical interventions exist for treating glaucoma, including a group of procedures commonly called micro-invasive or minimally invasive glaucoma surgery (MIGS). It has been noted that, across Canada, there is a growing demand for MIGS, as well as a rise in the use of MIGS procedures. At the same time, the cost of MIGS implantable devices can be considerable and inconsistencies appear to exist in some jurisdictions regarding coverage under public health insurance plans.

CADTH, in collaboration with Health Quality Ontario, undertook an Optimal Use project to assess the clinical effectiveness, safety, cost-effectiveness, patient perspectives and experiences, ethical issues, and implementation issues around MIGS devices and procedures for adults with glaucoma. 

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.


eye, filtering surgery, glaucoma, glaucoma drainage implants, microsurgery, minimally invasive surgical procedures, ophthalmologic surgical procedures, ophthalmology, sclerostomy, stents, trabeculectomy, medical devices, surgery, Antiglaucoma, MIGS, Minimally Invasive, OAG, POAG, Stent, eyes, micro, ocular, shunt, shunts